Connect with us

Roadmap Ahead

With great pleasure, we announce completion of three successful years of DiaSys India. During this short journey, we made memorable and notable accomplishments in the backdrop of very challenging economic environment in our country. Shifting manufacturing unit to spacious, state-of-the-art Mahape premises in March 2017 shows our commitment for providing high quality indigenous products. We launched many exciting products during these three glorious years and improved services in our bid to strive for perfection in every domain. We registered close to 20 percent annual sales growth over last year. DiaSys India employs 180+ employees in different functions located at various geographical locations.

Thanks to all our distributors who stood with us at all times, gave us constructive feedback and remained committed to our aggressive growth plans. Increased awareness amongst persons, high percentage of affordable population, reimbursements by insurance companies, exponential jump in life style related ailments has made IVD industry rise rapidly.

We have listed key enablers for meeting our ambitious, comprehensive agenda for strengthening our position in Indian market:

  • We now take this opportunity to announce launch of our newest and most exciting systems in DiaSys India product portfolio – 3-part (respons r3H) and 5-part (respons r5H) differential hematology analyzer. With this launch, we announce our foray in hematology segment.
  • Innovative technological advancements are rapidly changing healthcare landscape. We proudly boast existence of our research and development center in India. DiaSys India R&D is fostering innovation and is set to launch in-house developed product range starting with electrolyte analyzer by 3rd quarter of this year.
  • The art of Diagnostics is infinitely creative and it inspires us to continuously improve quality of our products. Through regular investments and employing skilled manpower, we seek to accelerate the introduction of processes, technologies, and regulations required to continuously roll out high quality products from our Mahape manufacturing unit.
  • This is also helping us build sustainability into our products and operations. We are adding 45 new employees in DiaSys family for strengthening all our company functions.
  • Our urine portfolio, rapids, PoC are set for higher growths this year through our focused approach and dedicated resources for doctor clinics in Tier II and Tier III cities. This will help doctors offer right and quality treatment to needy patients on time.
  • We completely understand dynamic nature of our systems in labs. Customer need systems to be functional round the clock to meet normal and emergency workload of patients. We have decided to improve after sales service as satisfied customers will help us in brand building and profit generation. A lot of emphasis is being given to recruitment and technical training of our engineers this year.

With our expertise and experience, we are clear on:

Arenas

  • l  Where will we be active geographically and product wise?
  • l  Who will be our core customers and what it takes for us to retain them?

Differentiators

  • l  What different will we do from our competitors?
  • l  How will we win?

In short, with right blend of products and aggressive people, DiaSys has embarked exciting journey with passionate commitment for profitable growth and giving paramount importance to customer satisfaction and patients’ welfare in India.

Copyright © 2024 Medical Buyer

error: Content is protected !!